Compositions and methods for treating cardiovascular related disorders

Abstract

The present invention relates to nanoparticles complexed with therapeutic agents configured for treating cardiovascular related disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising synthetic HDL (sHDL) nanoparticles carrying therapeutic agents configured for treating cardiovascular related disorders, methods for synthesizing such sHDL nanoparticles, as well as systems and methods utilizing such sHDL nanoparticles (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutic agents, imaging agents, and/or targeting agents (e.g., in cardiovascular disease diagnosis and/or therapy, etc.))).

We Claim: 
     
         1 . A method for preparing a synthetic HDL-therapeutic agent nanoparticle (sHDL-TA) comprising
 combining at least one phospholipid having a transition temperature, at least one therapeutic agent, and at least one HDL apolipoprotein in a solvent to produce a mixture;   lyophilizing the mixture to produce a dried mixture;   hydrating the dried mixture in an aqueous buffer to produce an aqueous mixture;   thermocycling the aqueous mixture above and below the phospholipid transition temperature to produce a sHDL-TA;   wherein the therapeutic agent is configured to treat a cardiovascular disorder;   wherein the HDL apolipoprotein is an HDL apolipoprotein mimetic.